Crescent Biopharma (CBIO) Net Income towards Common Stockholders Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.28% |
| Dec 31, 2025 | -42.17% |
| Sep 30, 2025 | -12.39% |
| Jun 30, 2025 | -9.13% |
| Mar 31, 2025 | -14.60% |
| Dec 31, 2024 | -3.94% |
| Sep 30, 2024 | 27.63% |
| Jun 30, 2024 | 8.60% |
| Mar 31, 2024 | 5.28% |
| Dec 31, 2023 | 8.18% |
| Sep 30, 2023 | 4.48% |
| Jun 30, 2023 | 6.86% |
| Mar 31, 2023 | 1.69% |
| Dec 31, 2022 | -1.44% |
| Sep 30, 2022 | -0.82% |
| Jun 30, 2022 | -9.98% |
| Mar 31, 2022 | -12.95% |
| Dec 31, 2021 | -15.82% |
| Sep 30, 2021 | -17.06% |
| Jun 30, 2021 | -12.21% |
| Mar 31, 2021 | -13.51% |
| Dec 31, 2020 | -11.86% |
| Sep 30, 2020 | -13.87% |
| Jun 30, 2020 | -27.39% |
| Mar 31, 2020 | -1.50% |
| Dec 31, 2019 | -14.76% |
| Sep 30, 2019 | -14.90% |
| Jun 30, 2019 | -31.82% |
| Mar 31, 2019 | -22.52% |
| Dec 31, 2018 | -29.17% |
| Sep 30, 2018 | -25.62% |
| Jun 30, 2018 | -27.50% |
| Mar 31, 2018 | -92.65% |